DPH001 – Pipeline project
Disruptive Pharma is leveraging its in-house expertise in MMC drug formulation to develop a proprietary pipeline based on established APIs with a significant improvement opportunity of the approved product.
Disruptive Pharma’s lead product candidate, DPH001 will be improved sorafenib based MMC amorphous reformulation of NEXAVAR®
NEXAVAR® is a protein kinase inhibitor, approved for the treatment of certain types of liver, kidney, and thyroid cancer in adults. Disruptive Pharma will leverage the amorphous stabilization properties of a MMC sorafenib formulation to demonstrate bioequivalence at reduced API dosing, expected to yield an improved tolerability profile.
Disruptive Pharma is seeking partnerships for its pipeline projects.